Stratified Medicine Advances Alzheimer's Disease Research by Identifying Genetic Modifiers of APOE Gene
A comprehensive genome-wide association study (GWAS) meta-analysis, stratified by apolipoprotein E (APOE) status, has provided new insights into the genetic underpinnings of Alzheimer's disease (AD). Researchers grouped individuals into different APOE strata (ε22 + ε32, ε33, and ε44 + ε43) to maximize statistical power and identify genomic signals that modify the effect of the APOE ε4 allele. The study identified 25 loci that reached genome-wide significance, with nine known AD risk loci found in both ε33 and ε44 + ε43 strata. Notably, nine loci were exclusively observed in the ε44 + ε43 stratum, including six known AD loci and three new ones (HP1BP3, PTPRC, DDHD1). Seven loci were exclusively significant in the ε33 stratum, with four known AD risk loci and three new ones (SCL50A1, NPAS3, CHST9). The research also performed interaction tests to identify variants where effect sizes were either attenuated or augmented with the presence of an ε4 allele, revealing genes like SLC50A1, TMEM106B, SHARPIN, and NPA...